Pharmacological Normalization of Pancreatic Cancer–Associated Fibroblast Secretome Impairs Pro-metastatic Cross-Talk With Macrophages

R., Samain, A., Brunel, T., Douché, M., Fanjul, S., Cassant-Sourdy, J., Rochotte, J., Cros, C., Neuzillet, J., Raffenne, C., Duluc, A., Perraud, J., Nigri, V., Gigoux, I., Bieche, M., Ponzo, G., Carpentier, I., Cascone, R., Tomasini, H.A., Schmid, M., Mathonnet, R., Nicolle, M.P., Bousquet, Y., Martineau, S., Pyronnet, C., Jean, Corinne, Bousquet

Cellular and Molecular Gastroenterology and Hepatology | 2021

Cancer-associated fibroblasts orchestrate pancreatic adeno- carcinoma (PDA) aggressiveness. We show that the Food and Drug Administration–approved somatostatin analog SOM230 inhibits metastasis in murine PDA models by acting through its receptor sst1 to disrupt the cancer-associated fibroblast production of colony stimulating factor 1, a prometastatic and macrophage-attracting chemokine whose stromal expression is associated with PDA aggressiveness.

https://doi.org/10.1016/j.jcmgh.2021.01.008